HuiHsing MAGeneral Partner, Life Sciences, TVM Capitals

Successful biomedical strategies need global reach across the pharma value chain. The imminent patent expiry of many blockbuster drugs and the unsatisfactory Pharmaceutical in-house R&D productivity are driving growing acceptance of Pharma-Biotech mutual symbiosis, new models of Pharma alliances and R&D outsourcing

This presents significant opportunities for growth in the New Biotech World Order, especially for those willing to embrace change. Companies are actively seeking higher growth markets to leverage their existing pipeline and brand as well as migrating and outsourcing their manufacturing and selected services towards geographies offering greater capital efficiency and access to scalable skilled resources.

Korean Life Sciences is a net beneficiary as it is one of the fastest growing pharmaceutical markets, enjoys competitive operating costs, offers access to a skilled biomedical talent pool and is supported by pro-healthcare and innovation government policies and incentives.